Loading...
Context Therapeutics Inc (CNTX) is not a good buy for a beginner, long-term investor at this time. The stock lacks positive catalysts, has weak financial performance, and no significant trading signals or trends to support a buy decision. Additionally, technical indicators and sentiment do not suggest a favorable entry point.
The stock's MACD is negatively expanding (-0.0346), RSI is neutral at 44.23, and moving averages are converging, indicating no clear trend. The stock closed below its pivot level (2.38) and is near its S1 support level (2.243), suggesting potential weakness.
NULL identified. There is no recent news, no significant insider or hedge fund activity, and no congressional trading data to suggest positive momentum.
The stock also experienced a regular market decline of -6.17% and a post-market decline of -1.53%. Technical indicators suggest weakness, and there are no significant trading trends or signals.
For Q3 2025, revenue remained at 0 with no growth, net income dropped to -$9,693,237 (-44.48% YoY), and EPS fell to -0.1 (-54.55% YoY). Gross margin remained at 0 with no improvement. These results indicate weak financial health and no growth momentum.
No analyst ratings or price target changes are available for CNTX.